ATXS
Astria Therapeutics, Inc. [ATXS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ATXS Stock Summary
Top 10 Correlated ETFs
ATXS
Top 10 Correlated Stocks
ATXS
In the News
ATXS Financial details
Company Rating
-
Market Cap
593.5M
Income
-70.59M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-4.32
Forward P/E
-
PEG
1.27
P/S
-
P/B
1.2
P/C
-
P/FCF
-5.88
Quick Ratio
20.12
Current Ratio
20.41
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.26
EPS next Y
-
EPS next Q
-
EPS this Y
-29.45%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
36.51%
-
-
-
-
SMA20
-7.82%
SMA50
-32.06%
SMA100
-40.8%
Inst Own
-
Inst Trans
-
ROA
-27%
ROE
-25%
ROC
-0.34%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.26-16.9
52W High
-57.44%
52W Low
+70.25%
RSI
31.94
Rel Volume
0.2
Avg Volume
1.04M
Volume
206.89K
Perf Week
-0.44%
Perf Month
-21.45%
Perf Quarter
-43.53%
Perf Half Y
-42.92%
-
-
-
-
Beta
0.707
-
-
Volatility
0.09%, 0.34%
Prev Close
-0.15%
Price
6.81
Change
-2.71%
Company Profile
- Volume Average 1.04M
- Market Capitalization 593.5M
- Employee 59
- CEO Ms. Jill C. Milne Ph.D.
- Headquarters Boston,MA,US
- IPO Date 2015-06-25
-
Website
https://www.astriatx.com 
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
